MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
30.27
-0.34
-1.11%
Opening 11:34 05/14 EDT
OPEN
30.50
PREV CLOSE
30.61
HIGH
31.01
LOW
29.95
VOLUME
543.25K
TURNOVER
--
52 WEEK HIGH
63.46
52 WEEK LOW
29.95
MARKET CAP
3.62B
P/E (TTM)
-5.7025
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Claritev (CTEV) and Cytokinetics (CYTK)
TipRanks · 4h ago
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Dow Jones · 4h ago
Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
Benzinga · 4h ago
Promising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
TipRanks · 13h ago
Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
TipRanks · 13h ago
Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
TipRanks · 13h ago
Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering
Seeking Alpha · 19h ago
BUZZ-U.S. STOCKS ON THE MOVE-Landsea Homes, Ameren, First Solar
Reuters · 21h ago
More
About CYTK
More
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Recently
Symbol
Price
%Change

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.